<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-90217</identifier>
<setSpec>1137-6627</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Complete response in a patient with a metastatic cutaneous melanoma</dc:title>
<dc:description xml:lang="en">Background. The management of patients withdisseminated disease is a difficult problem. Thereis currently no consensus on the standard first-linetreatment for metastatic melanoma. We present a casebecause of his exceptional evolution.Results. A 43 year old male diagnosed in 1999with malignant melanoma stage IIA. In May 2000, hepaticand splenic metastases were detected. He received6 cycles of biochemotherapy (cisplatin andDTIC, plus interleukin-2 and interferon-&amp;#945;) and another6 cycles with single immunotherapy (interleukin-2and interferon-&amp;#945;). Today, the patient is still alive andwithout evidence of disease.Conclusion. Metastatic cutaneous melanoma, sometimes,presents and unusual and favourable evolution. Inthe near future, the methods of detection of molecularmarkers are expected to identify factors involved in thistype of response. Furthermore, new targeted therapiesmay become essential to maintain this positive trend (AU)</dc:description>
<dc:creator>García-González, C</dc:creator>
<dc:creator>Lemos-Simosomo, M</dc:creator>
<dc:creator>Bermejo-Pérez, M. J</dc:creator>
<dc:creator>Galeote-Miguel, A. M</dc:creator>
<dc:creator>Villar-Chamorro, E</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Fundamento. El pronóstico del melanoma diseminadoes muy sombrío. Actualmente no hay consensosobre el tratamiento estándar en primera línea parael melanoma metastático. Se presenta un caso por sucomportamiento excepcional.Resultados. Varón de 43 años diagnosticado en1999 de melanoma maligno estadio IIA. En mayo de2000 se objetivaron metástasis hepáticas y esplénicas.Recibió 6 ciclos de bioquimioterapia (cisplatino y DTICjunto con interleukina-2 e interferón-&amp;#945;) cada 21 días yotros 6 ciclos con inmunoterapia sola (interleukina-2 einterferón-&amp;#945;). Actualmente el paciente sigue vivo y sinevidencia de enfermedad.Conclusión. El melanoma cutáneo metastático, enocasiones, presenta una inusual evolución favorable. Esde esperar que los métodos de detección de marcadoresmoleculares logren determinar factores implicadosen este tipo de respuesta y que los nuevos tratamientosdirigidos consigan mantener esta tendencia positiva (AU)</dc:description>
<dc:source>An Sist Sanit Navar;34(2): 307-310, mayo-ago. 2011.</dc:source>
<dc:identifier>ibc-90217</dc:identifier>
<dc:title xml:lang="es">Respuesta completa tras tratamiento con bioquimioterapia en un caso de melanoma cutáneo diseminado</dc:title>
<dc:subject>^d29622</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d8714^s22012</dc:subject>
<dc:subject>^d8714^s22067</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d8714^s22024</dc:subject>
<dc:subject>^d8714^s22058</dc:subject>
<dc:subject>^d9555^s22057</dc:subject>
<dc:subject>^d8714^s22059</dc:subject>
<dc:subject>^d9555^s22067</dc:subject>
<dc:subject>^d8714^s22053</dc:subject>
<dc:subject>^d8714^s22054</dc:subject>
<dc:subject>^d9555^s22016</dc:subject>
<dc:subject>^d8714^s22016</dc:subject>
<dc:subject>^d8714^s22027</dc:subject>
<dc:subject>^d9555^s22053</dc:subject>
<dc:type>article</dc:type>
<dc:date>201108</dc:date>
</metadata>
</record>
</ibecs-document>
